Karo Pharma publishes third-quarter report 2020 and resolves on sale of own shares
Q3, July - September · Net sales amounted to MSEK 679.1 (443.7). This corresponds to an increase of 53% for the period. Following very strong growth in the first quarter the organic growth during the third quarter was -10% which follows the same pattern as during the second quarter of the year. The currency impact in the quarter was 0% while the acquisition of Trimb in 2019 and the acquired product portfolios Proct® from Leo Pharma and Pevaryl® from Johnson & Johnson generate growth of 63%. · EBIT (Operating Profit) amounted to MSEK 43.7 (56.2) corresponding to a -22% decline. ·